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Abstract 
Botulinum toxin (BTX) is a neurotoxin protein derived from the Clostridium botulinum bacterium that inhibits the 
release of acetylcholine at the neuromuscular junction level whose effects has been used for many years to treat 
a variety of muscular/neuromuscular conditions and more recently also for cosmetic use. 
BTX has experimented in some dermatological conditions which include scar prevention and treatment with good 
results. The complex mechanism underlying those results is not completely understood but several mechanisms 
were proposed: release inhibition of different substances like (TGF)-β, substance P, calcitonin gene-related 
peptide (CGRP) and glutamate thus modulating cutaneous inflammation and wound healing. 
We analysed the published data on BTX off label applications on scars and keloids retrieved from PubMed. 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Botulinum toxin (BTX)is a neurotoxin protein 
derived from the Clostridium botulinum bacterium that 
inhibits the release of acetylcholine at the 
neuromuscular junction level causing temporary 
chemical denervation. At the synaptic level, BTX 
cleaves a docking protein (synaptosomal-associated 
protein of 25 kDa or SNAP-25) on the internal surface 
of neuronal membranes inhibiting vesicle fusion and 
thus the release of acetylcholine [1]. BTX effects are 
temporary and as SNAP-25 regenerates, contractility 
is restored in the affected muscles after a variable 
time of a few months. 
BTX effects have been used for many years 
to treat a variety of muscular/neuromuscular 
conditions and starting from 2002 also for cosmetic 
use [2].
 
More recently, BTX has experimented in 
some dermatological conditions which include scar 
prevention and treatment with good results [3], [4], [5]. 
The good results of those off label uses could be 
explained with the widely known interaction between 
skin and nervous system and is supposed that BTX 
Global Dermatology 
_______________________________________________________________________________________________________________________________ 
 
_______________________________________________________________________________________________________________________________ 
2980                                                                                                                                                                                              https://www.id-press.eu/mjms/index 
 
may inhibit the release of other substances like (TGF)-
β, substance P, calcitonin gene-related peptide 
(CGRP) and glutamate thus modulating cutaneous 
inflammation and wound healing [5], [6], [7]. 
 
 
Material and Methods 
 
We analysed the published data on BTX off 
label applications on scars and keloids retrieved from 
PubMed. We found 163 articles, from 2011 to April 
2019 using the terms “botulin scar” and correlated 
MeSH terms. Of these articles, only 44 were included 
in this review. Exclusion criteria were: case reports, 
duplicated studies, papers focusing on topics not 
related to dermatology or plastic surgery and articles 
written in languages other than English.  
 
 
Results 
 
BTX has been used to treat hypertrophic 
scars (HS) and keloids in a number of studies [8], [9], 
[10], [11], [12], [13], [14] and also was successfully 
used in scar prevention [14], [15], [16], [17], [18], [19], 
[20], [21]. Only a small number of available studies 
were made as randomized controlled trials with the 
efficacy of BTX compared to placebo (saline solution) 
or steroids, and those studies differ for the amount of 
BTX used ranging from 1.5 to 5 IU every cm
2
 and for 
the frequency of treatment ranging from a single 
treatment to multiple treatments done every month or 
even with longer intervals, but all gave positive 
results. 
Moreover, some animal studies demonstrated 
the usefulness of BTX in scar and keloid reduction 
[20], [21], [22]. Despite all differences in published 
studies a recent meta-analysis of randomised 
controlled trials evaluating BTX effect in the face/neck 
area has found that patients who received BTX had 
better outcomes than those who did not receive it [24]. 
According to this study the scars were significantly 
narrower (P = 0.006) and visual analogue scale 
scores were significantly better, indicating that 
patients treated with BTX were more satisfied with the 
results than those who received saline. However, the 
number of studies eligible for the analysis was only 9, 
and only 3 of these were completely unbiased. 
 
 
 
 
Discussion 
The molecular mechanism of BTX usefulness 
on hypertrophic scars and keloids is not yet perfectly 
explained but in vivo studies in animals and humans 
have demonstrated that, in addition to the known 
effects on acetylcholine release, BTX inhibits 
fibroblast proliferation (and hence collagen 
production). Also, it is reported to downregulate the 
expression of α-smooth muscle actin and myosin II 
proteins, which are found in fibroblasts in a dose-
dependent fashion [23]. Is important to note that these 
phenomena were not observed in fibroblasts isolated 
from normal skin [27].
 
Other studies indicated that, 
along with inhibition of fibroblast proliferation, 
production of transforming growth factor (TGF)-β1 and 
connective tissue growth factor were also diminished 
[25], [26], [27]. Unexpectedly collagen production and 
collagen organisation were found significantly 
improved with intralesional BTX than with saline in a 
rat model of burn healing and was associated with 
faster vascularisation and reepithelialisation of the 
wound [26].
 
To explain this phenomenon, it has been 
hypothesised that BTX may increase expression of 
Vascular endothelial growth factor (VEGF), and thus 
promote angiogenesis that hastens wound healing 
[29] and ultimately gave a better scar appearance, 
although the exact mechanism for this is not known. 
Results from studies investigating the effect of BTX on 
the expression of VEGF in scar healing are still 
inconsistent: some appear to demonstrate benefit, but 
others show no effect [28]. 
One particularly favourable aspect of BTX 
treatment is its ability to control the subjective 
symptoms of hypertrophic scars. We already know 
that BTX can immobilize the local muscles of a scar 
and reduce skin tension caused by the muscle pull 
which exacerbates inflammation and leads to 
overproduction of collagen and glycosaminoglycans, 
thus improving the cosmetic result of the scar, but 
also relieves trapped nerve fibers in keloids, 
neutralizing the itch and pain associated with small-
fiber neuropathy [30], [31]. The last know effect 
reported of BTX treatment is related to the inhibition of 
inflammatory mediators release such as substance P 
and calcitonin gene-related peptide (CGRP) [32], [33]. 
The reduction and control of local skin inflammation 
mediated by those cytokines may allow better overall 
healing resulting in a less evident scar. 
In conclusion, the innovative applications for 
BTX use in scar prevention or reduction, even if his 
complex mechanism is not completely understood, 
show very promising results. To better understand its 
therapeutic potential in dermatology, future studies 
should investigate the link between BTX and the 
cutaneous neuroimmune system and skin-nervous 
system interaction. Also, a consensus on the dose 
and regimen would be desirable to standardise the 
treatment. 
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